Tonix Pharmaceuticals (TNXP) Competitors $40.87 -1.49 (-3.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$40.66 -0.21 (-0.52%) As of 07/11/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. ARDX, AUPH, COLL, VERV, BGM, ELVN, NAGE, PRAX, CDTX, and AKBAShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Ardelyx (ARDX), Aurinia Pharmaceuticals (AUPH), Collegium Pharmaceutical (COLL), Verve Therapeutics (VERV), BGM Group (BGM), Enliven Therapeutics (ELVN), Niagen Bioscience (NAGE), Praxis Precision Medicines (PRAX), Cidara Therapeutics (CDTX), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Ardelyx Aurinia Pharmaceuticals Collegium Pharmaceutical Verve Therapeutics BGM Group Enliven Therapeutics Niagen Bioscience Praxis Precision Medicines Cidara Therapeutics Akebia Therapeutics Tonix Pharmaceuticals (NASDAQ:TNXP) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Which has higher valuation & earnings, TNXP or ARDX? Ardelyx has higher revenue and earnings than Tonix Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M29.81-$130.04M-$1.96 thousand-0.02Ardelyx$333.61M3.22-$39.14M-$0.22-20.41 Does the media favor TNXP or ARDX? In the previous week, Tonix Pharmaceuticals had 8 more articles in the media than Ardelyx. MarketBeat recorded 17 mentions for Tonix Pharmaceuticals and 9 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.75 beat Tonix Pharmaceuticals' score of 0.03 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, TNXP or ARDX? Tonix Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Is TNXP or ARDX more profitable? Ardelyx has a net margin of -14.86% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Ardelyx's return on equity of -34.45% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,313.87% -120.96% -101.28% Ardelyx -14.86%-34.45%-13.81% Do institutionals & insiders have more ownership in TNXP or ARDX? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer TNXP or ARDX? Tonix Pharmaceuticals currently has a consensus price target of $585.00, suggesting a potential upside of 1,331.37%. Ardelyx has a consensus price target of $10.89, suggesting a potential upside of 142.51%. Given Tonix Pharmaceuticals' higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryArdelyx beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.69M$2.42B$5.56B$9.11BDividend YieldN/A1.79%5.06%4.01%P/E Ratio-0.029.4228.2620.26Price / Sales29.81732.10437.10166.10Price / CashN/A164.4637.1257.67Price / Book1.284.608.045.49Net Income-$130.04M$31.26M$3.19B$250.45M7 Day Performance15.13%4.80%3.62%4.79%1 Month Performance27.80%8.17%5.98%9.59%1 Year Performance-32.03%-3.88%29.39%16.41% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals2.6716 of 5 stars$40.87-3.5%$585.00+1,331.4%-32.0%$300.69M$10.09M-0.0250Trending NewsARDXArdelyx4.1314 of 5 stars$4.34+1.5%$10.89+151.2%-23.8%$1.03B$333.61M-19.5790Analyst RevisionAUPHAurinia Pharmaceuticals3.0508 of 5 stars$7.47-1.6%$11.50+54.1%+56.9%$1.01B$235.13M26.66300Positive NewsCOLLCollegium Pharmaceutical4.2191 of 5 stars$31.11+2.5%$43.75+40.6%+2.3%$1.00B$631.45M25.52210Buyback AnnouncementGap UpVERVVerve Therapeutics3.0606 of 5 stars$11.21-0.7%$14.57+30.0%+63.9%$998.81M$32.33M-5.31110BGMBGM GroupN/A$10.14+1.1%N/AN/A$985.83M$25.10M0.00298ELVNEnliven Therapeutics2.822 of 5 stars$19.80-4.5%$41.20+108.1%-9.3%$975.51MN/A-10.3550Insider TradeNAGENiagen Bioscience1.3473 of 5 stars$12.33-3.0%$19.50+58.2%+333.0%$971.23M$99.60M72.53120PRAXPraxis Precision Medicines2.4442 of 5 stars$47.70+0.9%$92.11+93.1%-0.7%$966.96M$8.55M-4.43110Analyst ForecastCDTXCidara Therapeutics4.1372 of 5 stars$48.04-1.5%$57.14+19.0%+340.2%$966.67M$1.27M-1.6390Positive NewsAnalyst ForecastGap UpHigh Trading VolumeAKBAAkebia Therapeutics3.792 of 5 stars$3.67+1.2%$6.75+84.2%+211.9%$957.32M$160.18M-17.36430 Related Companies and Tools Related Companies Ardelyx Alternatives Aurinia Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Verve Therapeutics Alternatives BGM Group Alternatives Enliven Therapeutics Alternatives Niagen Bioscience Alternatives Praxis Precision Medicines Alternatives Cidara Therapeutics Alternatives Akebia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNXP Stock Alerts